

China's IP
in foreign eyes

China will build enough charging stations by 2020 to satisfy power demand for five million electric vehicles. The move is the latest effort to refuel the new energy vehicle sector, which has seen explosive growth in the past two years due to subsidies and tax cuts. (China to build charging stations to power electric cars, by Times of India)

到2020年,中国将建设足够的充电站,以满足500万辆电动汽车的充电需求。过去两年,受惠于补贴和减税,中国的新能源汽车呈现出爆炸式的增长,而建设充电站这一举动,是促进新能源汽车部门发展的最新举措。(《中国通过建设充电站促进电动汽车发展》,印度时报)

Comment:
In recent years, sales volume of new energy vehicle sector in China grows rapidly. In 2014, China sales 75 thousand new energy vehicles, 2.5 times more than last year. Meanwhile, the industry of new energy vehicles makes advances. Products from Chinese enterprises based on independent innovation, such as BYD and BAIC are welcomed by the consumers. With the widespread construction of charging station, the new energy vehicle industry may get into another high-speed track of development.

近年来,中国的新能源汽车销售量增长迅猛。2014年,新能源汽车销售7.5万辆,比上年增长2.5倍。与此同时,中国的新能源汽车行业也取得了良好的发展,比亚迪、北汽集团等中国企业自主创新的新能源汽车跑遍了中国的大街小巷。随着充电设施的普遍建设,中国的新能源汽车行业将进入下一个快速发展的轨道。



Lei Jun, co-founder and chief executive of Xiaomi, sat down with The Wall Street Journal. "Former Qualcomm global senior vice president Wang Xiang joined Xiaomi in July. He's in charge of our IP. We should be able to make progress in this. Xiaomi pays great attention to innovation. Last year we applied for 2,700 patents. This year's goal is 4,000." (It Had Better Get Bloodier: Q&A with Xiaomi's Lei Jun on China's Smartphone Battle, by Wall Street Journal)

雷军,小米的联合创始人和首席执行官在接受《华尔街日报》记者采访时表示:“前高通公司全球高级副总裁王翔7月份加盟小米,主管我们的知识产权工作,在这方面我们应该能够取得进步。小米高度重视创新,去年我们提交了2700件专利申请,今年的目标是4000件。”(“竞争越激烈越好”:关于中国的智能手机之战对话小米的雷军,华尔街日报)

Patents are more important for Chinese smartphone manufacturers because of the fierce competition in domestic market and the demand for expanding overseas market. The active patent layout strategy of Xiaomi reflects that smartphone makers of China pay more attention to Intellectual Property.

随着中国国内智能手机市场竞争激烈的竞争以及拓展海外市场的需要,专利对于小米的逐渐壮大显得愈发重要。小米积极开展专利布局,这是知识产权受到中国智能手机企业普遍重视的一个缩影。(孙易恒)

Patents make HengRui stand out

恒瑞医药成为中国首家对外转让创新生物药品的企业——

专利添彩 闪“药”全球

Recently, Jiangsu HengRui Medicine Co., Ltd. (hereinafter referred to as HengRui Medicine), licensed its overseas exclusive R&D and selling rights of PD-1 monoclonal antibody project with independent intellectual property rights to US-based Incyte with \$795 million, making itself the first Chinese company to transfer innovative biological drugs to foreign counterparts. The project, with its code name "SHR-1210", is specifically used in tumor immunological therapy.

Sun Piaoyang, president of HengRui Medicine indicated that the partnership with Incyte will step up R&D of SHR-1210 worldwide. He believes that when the products come into market in future, it will offer better treatment measures for global cancer patients, further enhancing company brand recognition and accelerating internationalized course of innovative drugs.

It is said that HengRui engaged in R&D of PD-1 monoclonal antibody project in 2012. So far, it filed many patent applications at home and abroad involving SHR-2120. Industry experts pointed out that the company's success demonstrated Chinese company's innovative capability. Domestic pharma-

ceutical companies should strengthen R&D especially in core domain. He emphasized that only by constantly accumulating technologies and vigorously conducting global patent layout, can Chinese companies win bigger markets in global competition.

For the past few years, HengRui has endeavored to drive innovation through enhanced international cooperation, R&D and promotion of high-quality products, speeding up technological transformation and upgrading, and therefore gained competitiveness in the field of innovative biological drugs. A principal of HengRui told CIP News reporter, that the company has increased the spending on R&D which accounted for 8% of total sales revenue and constantly optimized product portfolios. As of now, HengRui has over 200 patent filings covering areas such as drug combination and its applications, drug preparation and usage, and slow release preparation of medicinal salt. Moreover, the company submitted 119 international patent applications under Patent Cooperation Treaty (PCT). In terms of development of innovative biological drugs, HengRui has maintained a healthy momentum which every year there are at least one innovative drugs

entering the market.

"In recent years, domestic innovation-driven pharmaceutical companies represented by HengRui, Shandong GreenLeaf have successfully made a transition from being generic drugs-focused to being innovation-oriented which yielded satisfactory results," said Zhu Jingxi, legal manager of Nutrition and Health Research Institute under China Oil & Foodstuffs Corporation in an interview with CIP News. He added, as the pioneer company going out, HengRui manifested Chinese power due to its patent-first strategy when expanding foreign markets.

(by Chen Jingqiu)
日前,江苏恒瑞医药股份有限公司(下称恒瑞医药)以7.95亿美元的价格,将其拥有自主知识产权的用于肿瘤免疫治疗的PD-1单克隆抗体(代号"SHR-1210")项目的海外独家研发和销售权许可给美国Incyte公司,成为中国首家对外转让创新生物药品的企业。

恒瑞医药董事长孙飘扬表示,此次与美国Incyte公司的合作有助于加快SHR-1210在全球的开发进度,药品未来上市后将为全球肿瘤患者提供更好的治疗手段,也将进一步提升公司品牌知名度,加快创新药的国际化进程。

据了解,恒瑞医药自2012年开



始从事PD-1单克隆抗体的研发工作,目前已就SHR-1210在国内外提交了多件专利申请。业内专家表示,恒瑞医药的成功彰显了中国药企的创新力,未来国内药企应进一步加大技术研发力度,特别是在核心领域,只有通过不断积累技术,积极进行全球专利布局,才能让企业在全竞争中获得更大的市场。

据了解,近年来,恒瑞医药不断强化国际合作推动创新和高品质药品的研究、开发和推广,加快转型升级,在创新生物药品领域具有一定的竞争力。恒瑞医药相关负责人在接受本报记者采访时表示,近年来,公司持续加大创新投入,研发投入占销售收入的比例接近8%,并且不断对产品进行调整优化,产品布局向创新生物药品领域倾斜。截至目前,恒瑞医

药在中国共提交发明专利申请200余件,涉及领域包括药物组合物及其应用、药物的制备方法与用途、可药用盐的缓释制剂等。此外,该公司还通过《专利合作条约》(PCT)途径提交了国际专利申请119件。在创新生物药开发上,恒瑞医药已基本形成了每年都有多个创新药申请临床,每年都有1个至2个创新药上市的良性发展态势。

"近几年来,以恒瑞医药、山东绿叶制药为代表的国内创新型药企从最初关注仿制药到逐渐注重创新生物药品的研发,成果喜人。"中粮营养健康研究院知识产权法务经理朱镜羲在接受中国知识产权报记者采访时表示,作为率先"走出去"的医药领域的代表之一,恒瑞医药依靠专利先行的策略开疆拓土,彰显了"走出去"的中国力量。(陈景秋)

"Chengdu Lead" builds a channel to high-end industry chain

"为中国药企打造通往产业链高端的通道"

In 2013, the Innovative platform for DNA encoding small molecule synthesis and lead compound screening, led by Chengdu Lead Pharmaceutical Co., limited (hereinafter referred to as Chengdu Lead), completed the synthesis of 50 million DNA encoding small molecule compounds. As of June, 2014, Chengdu Lead has established 326 different DNA coding compound libraries including 563 million were compounds. It is estimated that by the end of 2015, the company will have finished the synthesis of 1 billion DNA coding compounds and screening of 70 biological targets, which means the company will be a world-class lead compound research platform and research center. The fact that the company achieved such great achievements shortly after being established is closely related to the founder Li Jin's personal experience.

Upon graduation, Li Jin went on his research in postdoctoral research station at Manchester University and made a fame in the field of design for small molecule drugs based on protein structure. Later, he served in global top 500 company AstraZeneca Pharmaceuticals in charge of global operation and improvement of the lead compound platform around the world.

Due to close contacts with China in daily work, Li Jin got to sensed that there has been great opportunity establishing businesses in China. In order to realize his dream of innovation, Li Jin went back to China and signed the cooperation agreement with Chengdu high-tech zone, setting up a lead compound screening platform at international advanced level. "Our team has established a complete and standardized technical operation process including design, synthesis, screening, sequencing and decoding of the DNA coding compound library, offering

complete, accurate and persuasive scientific data of active chemicals." Li Jin talked about his team with much pride.

"In the area dominated by multinational companies, our technology will provide a fast track for Chinese pharmaceutical companies staying at lower end to move to high-end of the industry chain. My dream is as long as the lead compound screening service is mentioned anywhere in the world, what comes into their mind is Chengdu, China, is our company." Li Jin said.

(by Zhou Yuli)
2013年,由成都先导药物开发有限公司(下称成都先导)主导的"DNA编码小分子化合物库合成与先导化合物筛选创新平台"完成了5000万个DNA编码小分子化合物的合成;截至2014年6月,成都先导构建了326个不同的DNA编码化合物库,化合物库中化合物数量已达5.63亿个;预计2015年底,公司将完成10亿个DNA

编码化合物的合成,完成70个生物靶标的筛选。这意味着,成都先导将成为世界级的先导化合物研发平台和研发中心。自公司创业至今短短的几年时间,成都先导就能取得这样的成绩,与公司创办人李进的经历密不可分。

大学毕业后的李进到英国攻读博士学位。毕业后,他来到英国名校曼彻斯特大学理论生物学专业博士后站继续他的研究,在"基于蛋白质结构的小分子药物设计"领域小有名气。凭借其研究成果,李进任职世界500强企业阿斯利康制药集团,负责阿斯利康先导化合物开发平台在全球的有效运作和改进。

随着在工作中与国内的接触不断增多,他感受到了国内强烈的创业氛围。为了实现中国药企的研发梦,李进在成都高新区搭建了具有国际先进水平的先导化合物筛选平台。"从DNA编码化合物库的设计、合成、筛选、测序、解码,到活性化合物确认,提供完整、准确、有说服力的科

学数据等,我们的团队建立了完整、规范的先导化合物技术平台操作流程。"李进谈到他的研发团队时充满自豪。

"在这个一直被跨国大公司占据的领域,我们的技术将一直处于制药产业链底端的中国药企找到了一条通往产业链高端的快速通道。我的梦想是,今后,全世界只要提到先导化合物筛选服务,就会想起中国成都,想到我们先导公司。"李进自豪地表示。(周渝利)



学数据等,我们的团队建立了完整、规范的先导化合物技术平台操作流程。"李进谈到他的研发团队时充满自豪。

"在这个一直被跨国大公司占据的领域,我们的技术将一直处于制药产业链底端的中国药企找到了一条通往产业链高端的快速通道。我的梦想是,今后,全世界只要提到先导化合物筛选服务,就会想起中国成都,想到我们先导公司。"李进自豪地表示。(周渝利)

Dongying beefs up IP enforcement

东营 专利行政执法高效化纠纷

No longer before, a principal of a DongYing-based company came to Dongying IP Office and read his letter of thanks aloud on the spot, delivering a silk banner inscribed "pioneer of safeguarding legal rights, sword of justice", to express his appreciation to officials for their efforts in handling the case with efficiency, justice and strictness.

It is known that the Dongying-based company was gradually on fast track relying on its patented products called "a combined tower crane base". The company unexpectedly encountered patent infringement. The company filed a request to Dongying IP Office for mediation. Receiving the

request, the office immediately went to the grassroots and investigated, interviewed the petitioner and the respondent, studied the evidence. Finally, the respondent took the initiative to promise to cease patent infringement and settle the dispute. The enforcement officials' efforts paid off, safeguarding the legal rights and interests of the patentee to the utmost extent.

A principal of the office told CIP News reporter that it has enhanced IP administrative protection, improved patent administrative law enforcement and more patent enforcement cases be disposed. It has handled a batch of major IP dispute cases, help-

ing citywide companies to recover economic losses worth billions yuan. "We will continue to enhance patent administrative enforcement, building favorable condition for companies to achieve innovative development," said the principal of the office.

(by Zhao Jian'guo)

本报记者 赵建国

"维护正义是你的职责,创造和谐是你的愿望。"前不久,东营市某公司负责人来到东营市知识产权局,将一面写有"维权先锋,正义之剑"的锦旗送到执法人员手中,并现场朗读了自己创作的感谢信,表达了对山东省东营市知识产权局专利行政执法人员高效办案、公正审理、严格执法的

真诚谢意。

据了解,东营市的这家公司依靠"一种组合式塔机基础"的专利产品,逐渐走上快速发展道路。这时,企业却遭遇了专利侵权。该公司就此专利侵权案向东营市知识产权局提起调处请求。市知识产权局立即开展调查,深入基层,现场办案,多次走访调查请求人和被请求人,掌握了证据,为当事人讲清法律、摆明事实。最后,经过专利行政执法人员耐心细致的调解,被请求人主动做出停止专利侵权行为的承诺,化解了纠纷,最大限度地维护了专利权人的合法权益。

东营市知识产权局有关负责人表示,近年来,该局加大知识产权行政执法保护力度,专利行政执法工作水平

显著提高,专利执法办案数量明显增长,重点处理了包括涉及外企在内的一批重大知识产权纠纷案件,为全市企业挽回经济损失数十亿元。"我们将继续加强专利行政执法,积极为企业营造创新发展的良好环境。"该负责人表示。



英文翻译	孙芳华
Translator	Sun Fanghua
责任编辑	王璐
Executive Editor	Wang Lu